http://www.jcps.ac.cn

Journal of Chinese Pharmaceutical Sciences ›› 2018, Vol. 27 ›› Issue (1): 22-30.DOI: 10.5246/jcps.2018.01.003

• Original articles • Previous Articles     Next Articles

Study on the interactions of pharmacokinetics and liver distributions between rosuvastatin and repaglinide in rats

Dujuan Zhang1, Keguang Chen2, Rui Zhang2, Guiyan Yuan2, Benjie Wang2, Ruichen Guo2*   

  1. 1. Department of pharmacy of Jinan maternity and child care hospital, Jinan 250001, China
    2. Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan 250012, China
  • Received:2017-10-15 Revised:2017-11-11 Online:2018-02-28 Published:2017-12-18
  • Contact: Tel.: +86-531-82169636; Fax: +86-531-86109975, E-mail: grc7636@126.com

Abstract:

In the present study,we aimed to investigate the interactions of pharmacokinetics and liver distributions between rosuvastatin and repaglinide in rats.Coadministration of repaglinide (0.5 mg/kg, 1 mg/kg and 2 mg/kg) for 7 d significantly increased the AUC0–24 and Cmax of rosuvastatin (P<0.01), but dramatically decreased the CL/F of rosuvastatin (P<0.01) after a single dose of rosuvastatin (10 mg/kg). There were no obviously changes in the parameters of Tmax and t1/2. Coadministration of repaglinide also decreased the liver distribution of rosuvastatin (P<0.01). Coadministration of rosuvastatin (20 mg/kg) for 7 days significantly increased the AUC0–12 and Cmax of repaglinide (P<0.05), and decreased the CL/F of repaglinide (P<0.01) after a single dose of repaglinide (1 mg/kg). The liver distribution of repaglinide was also decreased (P<0.01). Our animal study indicated that repaglinide could significantly affect the pharmacokinetics and liver distribution of rosuvastatin in rats and vice versa.

Key words: Rosuvastatin, Repaglinide, Pharmacokinetics, Drug-drug interaction, Liver distribution

CLC Number: 

Supporting: